Tag: tucatinib

HER2-Positive Breast Cancer: Targeted Therapies Explained

HER2-positive breast cancer, once aggressive, is now highly treatable with targeted therapies like trastuzumab, T-DXd, and tucatinib. Learn how these drugs work, their side effects, and why HER2-low is changing treatment for millions.

view more